Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 179491, 11 pages
http://dx.doi.org/10.1155/2010/179491
Review Article

Advances in Cellular Therapy for the Treatment of Thyroid Cancer

Endocrine Cancer Center, Department of Endocrinology, Diabetes, and Rheumatology, University Hospital Duesseldorf, Moorenstr.5, 40225 Duesseldorf, Germany

Received 2 September 2009; Accepted 6 May 2010

Academic Editor: Jennifer E. Rosen

Copyright © 2010 Claudia Papewalis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Benvenga, “Update on thyroid cancer,” Hormone and Metabolic Research, vol. 40, no. 5, pp. 323–328, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. X. G. Zhu and S. Y. Cheng, “Modeling thyroid cancer in the mouse,” Hormone and Metabolic Research, vol. 41, no. 6, pp. 488–499, 2009. View at Publisher · View at Google Scholar · View at PubMed
  3. J. A. Sipos and E. L. Mazzaferri, “The therapeutic management of differentiated thyroid cancer,” Expert Opinion on Pharmacotherapy, vol. 9, no. 15, pp. 2627–2637, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. V. V. Vasko and M. Saji, “Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis,” Current Opinion in Oncology, vol. 19, no. 1, pp. 11–17, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. S. Chiacchio, A. Lorenzoni, G. Boni, D. Rubello, R. Elisei, and G. Mariani, “Anaplastic thyroid cancer: prevalence, diagnosis and treatment,” Minerva Endocrinologica, vol. 33, no. 4, pp. 341–357, 2008. View at Google Scholar
  6. E. A. Ziad, M. Ruchala, J. Breborowicz, M. Gembicki, J. Sowinski, and M. Grzymislawski, “Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving,” Folia Histochemica et Cytobiologica, vol. 46, no. 4, pp. 461–464, 2008. View at Publisher · View at Google Scholar · View at PubMed
  7. P. I. Haigh, “Anaplastic thyroid carcinoma,” Current Treatment Options in Oncology, vol. 1, no. 4, pp. 353–357, 2000. View at Google Scholar
  8. R. C. Smallridge, L. A. Marlow, and J. A. Copland, “Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies,” Endocrine-Related Cancer, vol. 16, no. 1, pp. 17–44, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. C. J. Mooney, G. Nagaiah, and G. Nagaiah, “A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome,” Thyroid, vol. 19, no. 3, pp. 233–240, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. C. Conticello, L. Adamo, and L. Adamo, “Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 5, pp. 1938–1942, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. W. van Veelen, J. W. B. De Groot, D. S. Acton, R. M. W. Hofstra, J. W. M. Höppener, T. P. Links, and C. J. M. Lips, “Medullary thyroid carcinoma and biomarkers: past, present and future,” Journal of Internal Medicine, vol. 266, no. 1, pp. 126–140, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. G. Favia, M. Iacobone, S. Zanella, and F. A. Ciarleglio, “Management of invasive and advanced thyroid cancer,” Minerva Endocrinologica, vol. 34, no. 1, pp. 37–55, 2009. View at Google Scholar
  13. J. Banchereau, H. Ueno, and H. Ueno, “Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon,” Journal of Immunotherapy, vol. 28, no. 5, pp. 505–516, 2005. View at Google Scholar
  14. R. M. Steinman, “The dendritic cell system and its role in immunogenicity,” Annual Review of Immunology, vol. 9, pp. 271–296, 1991. View at Google Scholar
  15. G. Jego, A. K. Palucka, J.-P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau, “Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6,” Immunity, vol. 19, no. 2, pp. 225–234, 2003. View at Publisher · View at Google Scholar
  16. N. C. Fernandez, A. Lozier, and A. Lozier, “Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo,” Nature Medicine, vol. 5, no. 4, pp. 405–411, 1999. View at Publisher · View at Google Scholar · View at PubMed
  17. N. Kadowaki, S. Antonenko, and Y.-J. Liu, “Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN,” Journal of Immunology, vol. 166, no. 4, pp. 2291–2295, 2001. View at Google Scholar
  18. M. Schott, “Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers,” Endocrine-Related Cancer, vol. 13, no. 3, pp. 779–795, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. J. H. Peters, H. Xu, J. Ruppert, D. Ostermeier, D. Friedrichs, and R. K. H. Gieseler, “Signals required for differentiating dendritic cells from human monocytes in vitro,” Advances in Experimental Medicine and Biology, vol. 329, pp. 275–280, 1993. View at Google Scholar
  20. N. Romani, S. Gruner, and S. Gruner, “Proliferating dendritic cell progenitors in human blood,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 83–93, 1994. View at Publisher · View at Google Scholar
  21. F. Sallusto and A. Lanzavecchia, “Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α,” Journal of Experimental Medicine, vol. 179, no. 4, pp. 1109–1118, 1994. View at Google Scholar
  22. B. Jacobs, M. Wuttke, C. Papewalis, J. Seissler, and M. Schott, “Dendritic cell subtypes and in vitro generation of dendritic cells,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 99–107, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. T. Luft, K. C. Pang, E. Thomas, P. Hertzog, D. N. J. Hart, J. Trapani, and J. Cebon, “Type I IFNs enhance the terminal differentiation of dendritic cells,” Journal of Immunology, vol. 161, no. 4, pp. 1947–1953, 1998. View at Google Scholar
  24. R. L. Paquette, N. C. Hsu, S. M. Kiertscher, A. N. Park, L. Tran, M. D. Roth, and J. A. Glaspy, “Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells,” Journal of Leukocyte Biology, vol. 64, no. 3, pp. 358–367, 1998. View at Google Scholar
  25. S. M. Santini, C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli, “Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice,” Journal of Experimental Medicine, vol. 191, no. 10, pp. 1777–1788, 2000. View at Publisher · View at Google Scholar
  26. B. Jacobs, M. Wuttke, and M. Wuttke, “Characterization of monocyte-derived IFNα-generated dendritic cells,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 117–121, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. P. Chomarat, C. Dantin, L. Bennett, J. Banchereau, and A. K. Palucka, “TNF skews monocyte differentiation from macrophages to dendritic cells,” Journal of Immunology, vol. 171, no. 5, pp. 2262–2269, 2003. View at Google Scholar
  28. M. Mohamadzadeh, F. Berard, and F. Berard, “Interleukin 15 skews monocyte differentiation into dendritic cells with features of langerhans cells,” Journal of Experimental Medicine, vol. 194, no. 7, pp. 1013–1020, 2001. View at Publisher · View at Google Scholar
  29. T. Di Pucchio, L. Pilla, and L. Pilla, “Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors,” Cancer Research, vol. 66, no. 9, pp. 4943–4951, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. J. F. M. Jacobs, E. H. J. G. Aarntzen, and E. H. J. G. Aarntzen, “Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients,” Cancer Immunology, Immunotherapy, vol. 58, no. 1, pp. 145–151, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. E. Jäger, J. Karbach, and J. Karbach, “Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 39, pp. 14453–14458, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. K. Odunsi, F. Qian, and F. Qian, “Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12837–12842, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. D. Valmori, N. E. Souleimanian, and N. E. Souleimanian, “Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8947–8952, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. A. M. Asemissen and P. Brossart, “Vaccination strategies in patients with renal cell carcinoma,” Cancer Immunology, Immunotherapy, vol. 58, no. 7, pp. 1169–1174, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. P. Brossart, “Dendritic cells in vaccination therapies of malignant diseases,” Transfusion and Apheresis Science, vol. 27, no. 2, pp. 183–186, 2002. View at Publisher · View at Google Scholar
  36. L. Höltl, R. Ramoner, and R. Ramoner, “Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide,” Cancer Immunology, Immunotherapy, vol. 54, no. 7, pp. 663–670, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. D. J. Schendel, “Dendritic cell vaccine strategies for renal cell carcinoma,” Expert Opinion on Biological Therapy, vol. 7, no. 2, pp. 221–232, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. J. Wierecky, M. R. Müller, and M. R. Müller, “Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients,” Cancer Research, vol. 66, no. 11, pp. 5910–5918, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. Y. Akiyama, R. Tanosaki, and R. Tanosaki, “Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells,” Journal of Translational Medicine, vol. 3, no. 1, p. 4, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. Y. Akiyama, K. Maruyama, and K. Maruyama, “Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL Line from a Japanese metastatic melanoma patient,” Anticancer Research, vol. 29, no. 2, pp. 647–655, 2009. View at Google Scholar
  42. S. Fuessel, A. Meye, and A. Meye, “Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial,” Prostate, vol. 66, no. 8, pp. 811–821, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. Y. Waeckerle-Men, E. Uetz-Von Allmen, and E. Uetz-Von Allmen, “Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma,” Cancer Immunology, Immunotherapy, vol. 55, no. 12, pp. 1524–1533, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. S. Sbiera, S. Wortmann, and M. Fassnacht, “Dendritic cell based immunotherapy—a promising therapeutic approach for endocrine malignancies,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 89–98, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. A. M. Asemissen, D. Haase, and D. Haase, “Identification of an immunogenic HLA-A*0201-binding t-cell epitope of the transcription factor PAX2,” Journal of Immunotherapy, vol. 32, no. 4, pp. 370–375, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. T. P. Dick, S. Stevanović, W. Keilholz, T. Ruppert, U. Koszinowski, H. Schild, and H.-G. Rammensee, “The making of the dominant MHC class I ligand SYFPEITHI,” European Journal of Immunology, vol. 28, no. 8, pp. 2478–2486, 1998. View at Publisher · View at Google Scholar
  47. S. Mishra and S. Sinha, “Prediction and molecular modeling of T-cell epitopes derived from placental alkaline phosphatase for use in cancer immunotherapy,” Journal of Biomolecular Structure and Dynamics, vol. 24, no. 2, pp. 109–121, 2006. View at Google Scholar
  48. K. C. Parker, M. A. Bednarek, and J. E. Coligan, “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,” Journal of Immunology, vol. 152, no. 1, pp. 163–175, 1994. View at Google Scholar
  49. S. Adams, D. W. O'Neill, and D. W. O'Neill, “Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant,” Journal of Immunology, vol. 181, no. 1, pp. 776–784, 2008. View at Google Scholar
  50. C. Barrow, J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, and J. Cebon, “Tumor antigen expression in melanoma varies according to antigen and stage,” Clinical Cancer Research, vol. 12, no. 3 part 1, pp. 764–771, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. A. V. Bazhin, N. Wiedemann, M. Schnölzer, D. Schadendorf, and S. B. Eichmüller, “Expression of GAGE family proteins in malignant melanoma,” Cancer Letters, vol. 251, no. 2, pp. 258–267, 2007. View at Publisher · View at Google Scholar · View at PubMed
  52. T. Connerotte, P.A. Van, and P.A. Van, “Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities,” Cancer Research, vol. 68, no. 10, pp. 3931–3940, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. P. G. Coulie, V. Karanikas, and V. Karanikas, “Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen,” Immunological Reviews, vol. 188, pp. 33–42, 2002. View at Publisher · View at Google Scholar
  54. D. E. Joyner, T. A. Damron, A. Aboulafia, W. Bokor, J. D. Bastar, and R. L. Randall, “Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia,” Tissue Antigens, vol. 68, no. 1, pp. 19–27, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. L. Vence, A. K. Palucka, J. W. Fay, T. Ito, Y.-J. Liu, J. Banchereau, and H. Ueno, “Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20884–20889, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. N. N. Hunder, H. Wallen, and H. Wallen, “Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1,” New England Journal of Medicine, vol. 358, no. 25, pp. 2698–2703, 2008. View at Publisher · View at Google Scholar · View at PubMed
  57. A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen, “Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 5060–5069, 2006. View at Publisher · View at Google Scholar · View at PubMed
  58. M. Oelke, M. V. Maus, D. Didiano, C. H. June, A. Mackensen, and J. P. Schneck, “Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells,” Nature Medicine, vol. 9, no. 5, pp. 619–624, 2003. View at Publisher · View at Google Scholar · View at PubMed
  59. T. Kurokawa, M. Oelke, and A. Mackensen, “Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells,” International Journal of Cancer, vol. 91, no. 6, pp. 749–756, 2001. View at Publisher · View at Google Scholar
  60. N. T. Joncker and D. H. Raulet, “Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells,” Immunological Reviews, vol. 224, no. 1, pp. 85–97, 2008. View at Publisher · View at Google Scholar · View at PubMed
  61. L. L. Lanier, “Up on the tightrope: natural killer cell activation and inhibition,” Nature Immunology, vol. 9, no. 5, pp. 495–502, 2008. View at Publisher · View at Google Scholar · View at PubMed
  62. A. Iannello and A. Ahmad, “Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies,” Cancer and Metastasis Reviews, vol. 24, no. 4, pp. 487–499, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. H. Klingemann and L. Boissel, “Targeted cellular therapy with natural killer cells,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 122–125, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. R. V. Sorg, Z. Özcan, T. Brefort, J. Fischer, R. Ackermann, M. Müller, and P. Wernet, “Clinical-scale generation of dendritic cells in a closed system,” Journal of Immunotherapy, vol. 26, no. 4, pp. 374–383, 2003. View at Publisher · View at Google Scholar
  65. T. G. Berger, E. Strasser, R. Smith, C. Carste, B. Schuler-Thurner, E. Kaempgen, and G. Schuler, “Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells,” Journal of Immunological Methods, vol. 298, no. 1-2, pp. 61–72, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Erdmann, J. Dörrie, and J. Dörrie, “Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection,” Journal of Immunotherapy, vol. 30, no. 6, pp. 663–674, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. D. Schadendorf, S. Ugurel, and S. Ugurel, “Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG,” Annals of Oncology, vol. 17, no. 4, pp. 563–570, 2006. View at Publisher · View at Google Scholar · View at PubMed
  68. K. R. Meehan, J. Wu, S. M. Webber, A. Barber, Z. M. Szczepiorkowski, and C. Sentman, “Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy,” Cytotherapy, vol. 10, no. 1, pp. 30–37, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. M. M. Mueller and E. Seifried, “Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation,” Transfusion Clinique et Biologique, vol. 13, no. 5, pp. 282–289, 2006. View at Publisher · View at Google Scholar · View at PubMed
  70. J. Ayello, C. van de Ven, E. Cairo, J. Hochberg, L. Baxi, P. Satwani, and M. S. Cairo, “Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy,” Experimental Hematology, vol. 37, no. 10, pp. 1216–1229, 2009. View at Publisher · View at Google Scholar · View at PubMed
  71. J. J. Subleski, R. H. Wiltrout, and J. M. Weiss, “Application of tissue-specific NK and NKT cell activity for tumor immunotherapy,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 275–281, 2009. View at Publisher · View at Google Scholar · View at PubMed
  72. L. Zhang, M. Nakayama, and G. S. Eisenbarth, “Insulin as an autoantigen in NOD/human diabetes,” Current Opinion in Immunology, vol. 20, no. 1, pp. 111–118, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. L. G. P. de Marquesini, A. K. Moustakas, I. J. Thomas, L. Wen, G. K. Papadopoulos, and F. S. Wong, “Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands,” European Journal of Immunology, vol. 38, no. 1, pp. 240–249, 2008. View at Publisher · View at Google Scholar · View at PubMed
  74. F. S. Wong, J. Karttunen, and J. Karttunen, “Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library,” Nature Medicine, vol. 5, no. 9, pp. 1026–1031, 1999. View at Publisher · View at Google Scholar · View at PubMed
  75. A. R. Bradwell and T. C. Harvey, “Control of hypercalcaemia of parathyroid carcinoma by immunisation,” Lancet, vol. 353, no. 9150, pp. 370–373, 1999. View at Publisher · View at Google Scholar
  76. D. Betea, A. R. Bradwell, and A. R. Bradwell, “Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 7, pp. 3413–3420, 2004. View at Publisher · View at Google Scholar · View at PubMed
  77. F.-M. Michiels, S. Chappuis, and S. Chappuis, “Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3330–3335, 1997. View at Publisher · View at Google Scholar
  78. A. Machens, P. Niccoli-Sire, and P. Niccoli-Sire, “Early malignant progression of hereditary medullary thyroid cancer,” New England Journal of Medicine, vol. 349, no. 16, pp. 1517–1525, 2003. View at Publisher · View at Google Scholar · View at PubMed
  79. C. Papewalis, M. Wuttke, and M. Wuttke, “Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer,” Clinical Cancer Research, vol. 14, no. 13, pp. 4298–4305, 2008. View at Publisher · View at Google Scholar · View at PubMed
  80. M. Wuttke, C. Papewalis, and C. Papewalis, “Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma,” Endocrinology, vol. 149, no. 11, pp. 5627–5634, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. M. Schott, J. Feldkamp, M. Klucken, G. Kobbe, W. A. Scherbaum, and J. Seissler, “Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination,” Cancer Immunology, Immunotherapy, vol. 51, no. 11-12, pp. 663–668, 2002. View at Publisher · View at Google Scholar · View at PubMed
  82. M. Schott, J. Seissler, M. Lettmann, V. Fouxon, W. A. Scherbaum, and J. Feldkamp, “Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4965–4969, 2001. View at Publisher · View at Google Scholar
  83. D. Schattenberg, M. Schott, and M. Schott, “Response of human monocyte-derived dendritic cells to immunostimulatory DNA,” European Journal of Immunology, vol. 30, no. 10, pp. 2824–2831, 2000. View at Publisher · View at Google Scholar
  84. C. Papewalis, B. Jacobs, and B. Jacobs, “IFN-α skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo,” Journal of Immunology, vol. 180, no. 3, pp. 1462–1470, 2008. View at Google Scholar
  85. C. Papewalis, M. Wuttke, and M. Wuttke, “Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 108–116, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. S. Cheng, W. Liu, M. Mercado, S. Ezzat, and S. L. Asa, “Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 455–466, 2009. View at Publisher · View at Google Scholar · View at PubMed
  87. I. Ruschenburg, A. Kubitz, T. Schlott, M. Korabiowska, and M. Droese, “MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter,” International Journal of Molecular Medicine, vol. 4, no. 4, pp. 445–448, 1999. View at Google Scholar
  88. M. Milkovic, B. Sarcevic, and E. Glavan, “Expression of MAGE tumor-associated antigen in thyroid carcinomas,” Endocrine Pathology, vol. 17, no. 1, pp. 45–52, 2006. View at Publisher · View at Google Scholar
  89. G. Chakravarty, A. A. Santillan, and A. A. Santillan, “Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer,” Experimental Biology and Medicine, vol. 234, no. 4, pp. 372–386, 2009. View at Publisher · View at Google Scholar · View at PubMed
  90. Z. Wang, G. Chakravarty, and G. Chakravarty, “Growth-inhibitory effects of human anti-insulin-like growth factor-1 receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma,” Clinical Cancer Research, vol. 12, no. 15, pp. 4755–4765, 2006. View at Publisher · View at Google Scholar · View at PubMed
  91. L. A. Akslen and J. E. Varhaug, “Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival,” Cancer, vol. 76, no. 9, pp. 1643–1654, 1995. View at Publisher · View at Google Scholar
  92. G. O. Ness, D. R. F. Haugen, J. E. Varhaug, L. A. Akslen, and J. R. Lillehaug, “Cytoplasmic localization of EGF receptor in papillary thyroid carcinomas: association with the 150-kDa receptor form,” International Journal of Cancer, vol. 65, no. 2, pp. 161–167, 1996. View at Publisher · View at Google Scholar
  93. Z. Liu, P. Hou, and P. Hou, “Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3106–3116, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. J. M. Vieira, S. C. Rosa Santos, and S. C. Rosa Santos, “Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop,” European Journal of Endocrinology, vol. 153, no. 5, pp. 701–709, 2005. View at Publisher · View at Google Scholar · View at PubMed
  95. G. Yegen, M. A. Demir, Y. Ertan, O. A. Nalbant, and M. Tunçyürek, “Can CD10 be used as a diagnostic marker in thyroid pathology?” Virchows Archiv, vol. 454, no. 1, pp. 101–105, 2009. View at Publisher · View at Google Scholar · View at PubMed
  96. C. Tomoda, R. Kushima, E. Takeuti, K.-I. Mukaisho, T. Hattori, and H. Kitano, “CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma,” Thyroid, vol. 13, no. 3, pp. 291–295, 2003. View at Google Scholar
  97. M. D. Castellone, V. Guarino, and V. Guarino, “Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas,” Oncogene, vol. 23, no. 35, pp. 5958–5967, 2004. View at Publisher · View at Google Scholar · View at PubMed
  98. J. M. Cerutti, G. Oler, P. Michaluart Jr., R. Delcelo, R. M. Beaty, J. Shoemaker, and G. J. Riggins, “Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis,” Cancer Research, vol. 67, no. 16, pp. 7885–7892, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. T. Takano, Y. Hasegawa, and Y. Hasegawa, “Gene expression profiles in thyroid carcinomas,” British Journal of Cancer, vol. 83, no. 11, pp. 1495–1502, 2000. View at Google Scholar
  100. D. Li, A. Butt, S. Clarke, and R. Swaminathan, “Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects,” Annals of the New York Academy of Sciences, vol. 1022, pp. 147–151, 2004. View at Publisher · View at Google Scholar · View at PubMed
  101. E. Hesse, P. B. Musholt, and P. B. Musholt, “Oncofoetal fibronectin—a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma,” British Journal of Cancer, vol. 93, no. 5, pp. 565–570, 2005. View at Publisher · View at Google Scholar · View at PubMed
  102. M. R. Nasr, S. Mukhopadhyay, S. Zhang, and A.-L. A. Katzenstein, “Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining,” Modern Pathology, vol. 19, no. 12, pp. 1631–1637, 2006. View at Publisher · View at Google Scholar · View at PubMed
  103. M. Papotti, J. Rodriguez, R. De Pompa, A. Bartolazzi, and J. Rosai, “Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential,” Modern Pathology, vol. 18, no. 4, pp. 541–546, 2004. View at Publisher · View at Google Scholar · View at PubMed
  104. Y. Ito, H. Yoshida, and H. Yoshida, “Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma,” Oncology Reports, vol. 10, no. 5, pp. 1337–1340, 2003. View at Google Scholar
  105. T. Takano, Y. Ito, F. Matsuzuka, A. Miya, K. Kobayashi, H. Yoshida, and A. Miyauchi, “Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines,” Oncology Reports, vol. 18, no. 3, pp. 715–720, 2007. View at Google Scholar
  106. C. B. Umbricht, G. T. Conrad, and G. T. Conrad, “Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors,” Clinical Cancer Research, vol. 10, no. 17, pp. 5762–5768, 2004. View at Publisher · View at Google Scholar · View at PubMed
  107. M. Saji, S. Xydas, and S. Xydas, “Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms,” Clinical Cancer Research, vol. 5, no. 6, pp. 1483–1489, 1999. View at Google Scholar
  108. S.-L. Wang, W.-T. Chen, M.-T. Wu, H.-M. Chan, S.-F. Yang, and C.-Y. Chai, “Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study,” Endocrine Pathology, vol. 16, no. 3, pp. 211–218, 2005. View at Publisher · View at Google Scholar
  109. H. Tan, K. Ye, Z. Wang, and H. Tang, “Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma,” Japanese Journal of Clinical Oncology, vol. 38, no. 8, pp. 528–533, 2008. View at Publisher · View at Google Scholar · View at PubMed
  110. M. K. Cho, T. Eimoto, H. Tateyama, Y. Arai, Y. Fujiyoshi, and M. Hamaguchi, “Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions,” Histopathology, vol. 48, no. 3, pp. 286–294, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. Y. Ito, H. Yoshida, K. Kakudo, Y. Nakamura, K. Kuma, and A. Miyauchi, “Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma,” Pathology, vol. 38, no. 5, pp. 421–425, 2006. View at Publisher · View at Google Scholar · View at PubMed
  112. D. Buergy, T. Weber, G. D. Maurer et al., “Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies,” International Journal of Cancer, vol. 125, no. 4, pp. 894–901, 2009. View at Publisher · View at Google Scholar · View at PubMed
  113. B. Sid, B. Langlois, H. Sartelet, G. Bellon, S. Dedieu, and L. Martiny, “Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 9, pp. 1890–1900, 2008. View at Publisher · View at Google Scholar · View at PubMed
  114. G. Chen, F.-R. Zhang, and F.-R. Zhang, “Expression of fascin in thyroid neoplasms: a novel diagnostic marker,” Journal of Cancer Research and Clinical Oncology, vol. 134, no. 9, pp. 947–951, 2008. View at Publisher · View at Google Scholar · View at PubMed
  115. A. Kehlen, N. Englert, A. Seifert, T. Klonisch, H. Dralle, J. Langner, and C. Hoang-Vu, “Expression, regulation and function of autotaxin in thyroid carcinomas,” International Journal of Cancer, vol. 109, no. 6, pp. 833–838, 2004. View at Publisher · View at Google Scholar · View at PubMed
  116. A. Seifert, T. Klonisch, and T. Klonisch, “The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells,” Oncology Reports, vol. 19, no. 6, pp. 1485–1491, 2008. View at Google Scholar
  117. G. Zito, P. Richiusa, and P. Richiusa, “In vitro identification and characterization of CD133pos cancer stem-like cells in anaplastic thyroid carcinoma cell lines,” PLoS ONE, vol. 3, no. 10, article e3544, 2008. View at Publisher · View at Google Scholar · View at PubMed
  118. S. Friedman, M. Lu, A. Schultz, D. Thomas, and R.-Y. Lin, “CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin,” PLoS ONE, vol. 4, no. 4, article e5395, 2009. View at Publisher · View at Google Scholar · View at PubMed
  119. M. Maio, S. Coral, and S. Coral, “Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 2, pp. 748–754, 2003. View at Publisher · View at Google Scholar
  120. M. Wuttke, C. Papewalis, B. Jacobs, and M. Schott, “Identifying tumor antigens in endocrine malignancies,” Trends in Endocrinology and Metabolism, vol. 20, no. 3, pp. 122–129, 2009. View at Publisher · View at Google Scholar · View at PubMed
  121. C. Uyttenhove, C. Godfraind, and C. Godfraind, “The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen,” International Journal of Cancer, vol. 70, no. 3, pp. 349–356, 1997. View at Publisher · View at Google Scholar
  122. A. Ciampolillo, C. De Tullio, E. Perlino, and E. Maiorano, “The IGF-I axis in thyroid carcinoma,” Current Pharmaceutical Design, vol. 13, no. 7, pp. 729–735, 2007. View at Publisher · View at Google Scholar
  123. A. Ciampolillo, C. De Tullio, and F. Giorgino, “The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer,” Current Medicinal Chemistry, vol. 12, no. 24, pp. 2881–2891, 2005. View at Publisher · View at Google Scholar
  124. C. S. Mitsiades, N. S. Mitsiades, and N. S. Mitsiades, “Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors,” Cancer Cell, vol. 5, no. 3, pp. 221–230, 2004. View at Publisher · View at Google Scholar
  125. J.-D. Lin, “Thyroglobulin and human thyroid cancer,” Clinica Chimica Acta, vol. 388, no. 1-2, pp. 15–21, 2008. View at Publisher · View at Google Scholar · View at PubMed
  126. R. M. Tuttle, R. Leboeuf, and A. J. Martorella, “Papillary thyroid cancer: monitoring and therapy,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 3, pp. 753–778, 2007. View at Publisher · View at Google Scholar · View at PubMed
  127. S. Rorive, B. Eddafali, and B. Eddafali, “Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications,” Modern Pathology, vol. 15, no. 12, pp. 1294–1301, 2002. View at Publisher · View at Google Scholar · View at PubMed
  128. T. H. Than, G. K. Swethadri, and G. K. Swethadri, “Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators,” Singapore Medical Journal, vol. 49, no. 4, pp. 333–338, 2008. View at Google Scholar
  129. L. Giovanella, L. Ceriani, A. Ghelfo, and M. Maffioli, “Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland,” International Journal of Biological Markers, vol. 23, no. 1, pp. 54–57, 2008. View at Google Scholar
  130. S. Califice, V. Castronovo, and F. Van Den Brûle, “Galectin-3 and cancer (Review),” International Journal of Oncology, vol. 25, no. 4, pp. 983–992, 2004. View at Google Scholar
  131. R. C. Hughes, “Galectins as modulators of cell adhesion,” Biochimie, vol. 83, no. 7, pp. 667–676, 2001. View at Publisher · View at Google Scholar
  132. I. Honma, H. Kitamura, and H. Kitamura, “Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1803–1809, 2009. View at Publisher · View at Google Scholar · View at PubMed
  133. M. Croce, R. Meazza, and R. Meazza, “Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen,” Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1625–1634, 2008. View at Publisher · View at Google Scholar · View at PubMed
  134. H.-I. Cho, E.-K. Kim, S.-Y. Park, S. K. Lee, Y.-K. Hong, and T.-G. Kim, “Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein,” Cancer Letters, vol. 258, no. 2, pp. 189–198, 2007. View at Publisher · View at Google Scholar · View at PubMed
  135. S. M. Domchek, A. Recio, and A. Recio, “Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance,” Cancer Research, vol. 67, no. 21, pp. 10546–10555, 2007. View at Publisher · View at Google Scholar · View at PubMed
  136. D. Mavroudis, I. Bolonakis, and I. Bolonakis, “A phase I study of the optimized cryptic peptide TERT(572Y) in patients with advanced malignancies,” Oncology, vol. 70, no. 4, pp. 306–314, 2006. View at Publisher · View at Google Scholar · View at PubMed
  137. R. H. Vonderheide, “Prospects and challenges of building a cancer vaccine targeting telomerase,” Biochimie, vol. 90, no. 1, pp. 173–180, 2008. View at Publisher · View at Google Scholar · View at PubMed
  138. Z. Pasieka, K. Kuzdak, W. Czyz, H. Stepień, and J. Komorowski, “Soluble intracellular adhesion molecules (sICAM-1, sVCAM-1) in peripheral blood of patients with thyroid cancer,” Neoplasma, vol. 51, no. 1, pp. 34–37, 2004. View at Google Scholar
  139. J. Komorowski, Z. Pasieka, J. Jankiewicz-Wika, and H. Stepień, “Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer,” Thyroid, vol. 12, no. 8, pp. 655–662, 2002. View at Google Scholar
  140. M. W. Yeh, J.-P. Rougier, J.-W. Park et al., “Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A,” Endocrine-Related Cancer, vol. 13, no. 4, pp. 1173–1183, 2006. View at Publisher · View at Google Scholar · View at PubMed
  141. B. Rothhut, C. Ghoneim, F. Antonicelli, and M. Soula-Rothhut, “Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase,” Biochimie, vol. 89, no. 5, pp. 613–624, 2007. View at Publisher · View at Google Scholar · View at PubMed
  142. S. M. Wiseman, O. L. Griffith, and O. L. Griffith, “Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma,” Archives of Surgery, vol. 142, no. 8, pp. 717–727, 2007. View at Publisher · View at Google Scholar · View at PubMed
  143. S. M. Wiseman, A. Melck, and A. Melck, “Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis,” Annals of Surgical Oncology, vol. 15, no. 10, pp. 2811–2826, 2008. View at Publisher · View at Google Scholar · View at PubMed
  144. M. Broecker-Preuss, S.-Y. Sheu, and S.-Y. Sheu, “Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma,” Hormone and Metabolic Research, vol. 40, no. 10, pp. 685–691, 2008. View at Publisher · View at Google Scholar · View at PubMed
  145. J. M. Dziba and K. B. Ain, “Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2127–2135, 2004. View at Publisher · View at Google Scholar
  146. S. Mocellin and D. Nitti, “Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines,” Medicinal Research Reviews, vol. 28, no. 3, pp. 413–444, 2008. View at Publisher · View at Google Scholar · View at PubMed
  147. J. L. Frazier, J. E. Han, M. Lim, and A. Olivi, “Immunotherapy combined with chemotherapy in the treatment of tumors,” Neurosurgery Clinics of North America, vol. 21, no. 1, pp. 187–194, 2010. View at Publisher · View at Google Scholar · View at PubMed
  148. R. Ramakrishnan, D. Assudani, S. Nagaraj et al., “Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1111–1124, 2010. View at Publisher · View at Google Scholar · View at PubMed
  149. M. L. Salem and D. J. Cole, “Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination,” Cancer Immunology, Immunotherapy, vol. 59, no. 3, pp. 341–353, 2010. View at Publisher · View at Google Scholar · View at PubMed
  150. M. Schlumberger and S. I. Sherman, “Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances,” Thyroid, vol. 19, no. 12, pp. 1393–1400, 2009. View at Publisher · View at Google Scholar · View at PubMed
  151. S. I. Sherman, L. J. Wirth, and L. J. Wirth, “Motesanib diphosphate in progressive differentiated thyroid cancer,” New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008. View at Publisher · View at Google Scholar · View at PubMed
  152. S. A. Wells Jr., J. E. Gosnell, R. F. Gagel et al., “Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 767–772, 2010. View at Publisher · View at Google Scholar · View at PubMed
  153. J. Ozao-Choy, M. Ge, and M. Ge, “The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies,” Cancer Research, vol. 69, no. 6, pp. 2514–2522, 2009. View at Publisher · View at Google Scholar · View at PubMed
  154. R. Seggewiss, K. Loré, and K. Loré, “Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner,” Blood, vol. 105, no. 6, pp. 2473–2479, 2005. View at Publisher · View at Google Scholar · View at PubMed
  155. F. Abe, I. Younos, and I. Younos, “Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice,” International Immunopharmacology, vol. 10, no. 1, pp. 140–145, 2010. View at Publisher · View at Google Scholar · View at PubMed
  156. C. Borg, M. Terme, and M. Terme, “Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects,” Journal of Clinical Investigation, vol. 114, no. 3, pp. 379–388, 2004. View at Publisher · View at Google Scholar
  157. M. Terme, E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel, “Natural killer cell-directed therapies: moving from unexpected results to successful strategies,” Nature Immunology, vol. 9, no. 5, pp. 486–494, 2008. View at Publisher · View at Google Scholar · View at PubMed
  158. D. Wolf, H. Tilg, H. Rumpold, G. Gastl, and A. M. Wolf, “The kinase inhibitor Imatinib—an immunosuppressive drug?” Current Cancer Drug Targets, vol. 7, no. 3, pp. 251–258, 2007. View at Publisher · View at Google Scholar
  159. H. van Cruijsen, A. A. M. Van Der Veldt, and A. A. M. Van Der Veldt, “Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival,” Clinical Cancer Research, vol. 14, no. 18, pp. 5884–5892, 2008. View at Publisher · View at Google Scholar · View at PubMed
  160. A. Lissina, K. Ladell, and K. Ladell, “Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers,” Journal of Immunological Methods, vol. 340, no. 1, pp. 11–24, 2009. View at Publisher · View at Google Scholar · View at PubMed